April 27, 2020 / 8:07 PM / a month ago

BRIEF-I-Mab And Morphosys Announce First Patient Dosed In Phase 3 Clinical Trial Of Tj202/Mor202 In R/R Multiple Myeloma In Mainland China

April 27 (Reuters) - I-Mab:

* I-MAB AND MORPHOSYS ANNOUNCE FIRST PATIENT DOSED IN PHASE 3 CLINICAL TRIAL OF TJ202/MOR202 IN R/R MULTIPLE MYELOMA IN MAINLAND CHINA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below